Home›Companies›Biotech & Pharma›Axelyf

Axelyf, Inc.

Develops RNA medicines for people with cancer and autoimmune diseases.

Updated Nov 9, 2026·Latest SEC filing Oct 13, 2026·Suggest an edit

About Axelyf

Axelyf is a private company based in Chestnut Hill, Massachusetts, incorporated in 2025 in Delaware. It has reported $7,473,572 raised in two offerings on Form D since August 2025. Its chief executive is Orn Almarsson.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Oct 7, 2026Oct 13, 2026$2,631,439of $2.7M target8$328KEquityRule 506(b)Form D ↗
Jul 25, 2025Aug 7, 2025$4,842,133of $6.3M target37$130KEquityRule 506(b)Form D ↗
Total, two offerings$7,473,572

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Axelyf's Form D filed Oct 13, 2026.

OA
Orn Almarsson
CEO, Co-founder and director
AB
Arni Blondal
Director

Earlier filings also listed John Lucas (director, last listed Aug 2025).

Sources

  1. SECAxelyf, Inc. filing history
  2. CompanyAbout Axelyf
  3. CompanyAxelyf team